{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:50:09Z","timestamp":1791985809348,"version":"4.4.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by the presence of thrombosis and\/or pregnancy morbidity with persistently positive antiphospholipid antibodies (aPL). Due to the heterogeneity and relative rarity of this disorder, clinical practice in the management of APS remains varied. In this retrospective UK-wide multicenter study, we aimed to delineate clinical practice and outcomes in thrombotic APS to improve the areas of limited knowledge, particularly anticoagulant practice, thrombotic recurrence, and bleeding. Anticoagulation in Antiphospholipid Syndrome is the largest multicenter observational study to date, spanning 20 National Health Service trusts in the UK, and including 500 adult patients (aged \u226518 years) with thrombotic APS, on or off anticoagulation during 2012-2021. Thrombotic APS is primarily treated with vitamin K antagonists; however, the rates of recurrent thrombosis remain high. In the last decade, recurrent thrombosis occurred in 43 of 125 (34.4%), 31 of 95 (32.6%), and 37 of 93 (39.8%) patients with single-, dual-, and triple-positive aPL, respectively, with a recurrence rate of 46%. There was no difference in the probability of recurrent thrombosis based on the number of positive aPL tests (P = .82), especially in the first 3 years. However, the probability of recurrent thrombosis was significantly higher in patients with lupus anticoagulant (P&amp;lt; .01) compared with the presence of other antibodies. There was a higher probability of recurrence in patients with arterial than venous thrombosis (P = .03). Overall, the 10-year bleeding rate was 22.0%, with 6.7% of patients having major bleeding. Identifying patients with APS at higher risk of recurrent thrombosis remains a challenge, and current risk stratification is not adequate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019447","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:07:27Z","timestamp":1771618047000},"page":"3264-3275","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Anticoagulation, recurrent thrombosis, and major bleeding in antiphospholipid syndrome: UK multicenter observational study"],"prefix":"10.1182","volume":"10","author":[{"given":"Christina","family":"Crossette-Thambiah","sequence":"first","affiliation":[{"name":"1Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom"},{"name":"2Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indika","family":"Rajakaruna","sequence":"additional","affiliation":[{"name":"3Department of Computer Science and Digital Technologies, University of East London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5176-4364","authenticated-orcid":false,"given":"Zain","family":"Odho","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Doyle","sequence":"additional","affiliation":[{"name":"4Haemostasis and Thrombosis Centre, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Breen","sequence":"additional","affiliation":[{"name":"4Haemostasis and Thrombosis Centre, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-3268","authenticated-orcid":false,"given":"Michael","family":"Laffan","sequence":"additional","affiliation":[{"name":"1Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa J.","family":"Arachchillage","sequence":"additional","affiliation":[{"name":"1Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom"},{"name":"2Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Simini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Gameil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nini","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Yuan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Benton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Duffell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saniya","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Altohami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Hmaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Abuqamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunaid","family":"Chunara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Salta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Challenor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pip","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Buka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Nkem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kat","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Millen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bashford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajakta","family":"Pardeshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Mounter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Gyansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Dutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Badu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Langridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Osama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Glancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Chattree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Langridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Musgrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Likupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"issue":"1","key":"2026060113313930500_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13317-019-0113-9","article-title":"Anti-\u03b22-glycoprotein I and anti-phosphatidylserine\/prothrombin antibodies exert similar pro-thrombotic effects in peripheral blood monocytes and endothelial cells","volume":"10","author":"Cif\u00f9","year":"2019","journal-title":"Auto Immun Highlights"},{"issue":"2","key":"2026060113313930500_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2026060113313930500_bib3","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026060113313930500_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.16431","article-title":"What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br J Haematol"},{"issue":"13","key":"2026060113313930500_bib5","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2026060113313930500_bib6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16308","article-title":"Addendum to British Society for Haematology Guidelines on investigation and management of antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2026060113313930500_bib7","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/jth.12917","article-title":"Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome","volume":"13","author":"Arachchillage","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026060113313930500_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"6","key":"2026060113313930500_bib9","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026060113313930500_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026060113313930500_bib11","doi-asserted-by":"crossref","first-page":"102724","DOI":"10.1016\/j.rpth.2025.102724","article-title":"Unresolved issues in the diagnosis and management of thrombotic antiphospholipid syndrome","volume":"9","author":"Arachchillage","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2026060113313930500_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026060113313930500_bib13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on lupus anticoagulant\/antiphospholipid antibodies","volume":"23","author":"Devreese","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026060113313930500_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.thromres.2013.11.012","article-title":"Risk factors for arterial thrombosis in antiphospholipid syndrome","volume":"133","author":"Matyja-Bednarczyk","year":"2014","journal-title":"Thromb Res"},{"issue":"3","key":"2026060113313930500_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1365-2141.1997.d01-2055.x","article-title":"Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant","volume":"96","author":"Nojima","year":"1997","journal-title":"Br J Haematol"},{"issue":"4","key":"2026060113313930500_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0002-9343(96)00226-4","article-title":"Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study","volume":"101","author":"Zuckerman","year":"1996","journal-title":"Am J Med"},{"key":"2026060113313930500_bib17","doi-asserted-by":"crossref","first-page":"1196800","DOI":"10.3389\/fmed.2023.1196800","article-title":"Antithrombotic therapy in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis","volume":"10","author":"Attachaipanich","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2026060113313930500_bib18","doi-asserted-by":"crossref","first-page":"e000579","DOI":"10.1136\/lupus-2021-000579","article-title":"Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus","volume":"8","author":"Bolla","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"5","key":"2026060113313930500_bib19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0961203315617538","article-title":"Patients with antiphospholipid syndrome and thrombotic recurrences: a real world observation (the Piedmont cohort study)","volume":"25","author":"Bazzan","year":"2016","journal-title":"Lupus"},{"issue":"10","key":"2026060113313930500_bib20","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2026060113313930500_bib21","first-page":"234","article-title":"Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study","volume":"31","author":"Stojanovich","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"2026060113313930500_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.autrev.2013.11.004","article-title":"Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Reynaud","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"8","key":"2026060113313930500_bib23","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.jtha.2024.03.027","article-title":"Dilemmas in the diagnosis and management of antiphospholipid syndrome","volume":"22","author":"Manning","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026060113313930500_bib24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/ijms24021331","article-title":"Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome","volume":"24","author":"Arachchillage","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026060113313930500_bib25","doi-asserted-by":"crossref","first-page":"117968","DOI":"10.1016\/j.biopha.2025.117968","article-title":"S-hydroxychloroquine prevents the antiphospholipid thrombogenic complexes for antiphospholipid syndrome treatment","volume":"186","author":"Hsieh","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2026060113313930500_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2026060113313930500_bib27","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"issue":"4","key":"2026060113313930500_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/09612033251322927","article-title":"Risk factors for bleeding in patients with thrombotic antiphospholipid syndrome during antithrombotic therapy","volume":"34","author":"Gaspar","year":"2025","journal-title":"Lupus"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3264\/2516935\/blooda_adv-2025-019447-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3264\/2516935\/blooda_adv-2025-019447-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:31:45Z","timestamp":1780335105000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3264\/566676\/Anticoagulation-recurrent-thrombosis-and-major"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019447","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,4]]}}}